Trial Status: Closed to recruitment - in follow up
A phase III, interventional, international, multicentre, randomized, repeated dose, double blind, 3-
arm parallel groups, comparative study in patients with moderate to severe pain after impacted third
molar extraction.
The patients will be randomized in a 1:1:1 ratio to one of the 3 treatment groups:
1. FDC nefopam hydrochloride 30 mg / paracetamol 500 mg (x2)
2. Paracetamol 500 mg (x2)
3. Nefopam hydrochloride 30 mg (x2)